Lumexa Imaging Q3 revenue rises, swings to net profit

Overview

• US outpatient imaging provider's Q3 revenue rose

• Adjusted EPS for Q3 was $0.26

• Company posted net profit after loss a year earlier

Outlook

• Lumexa Imaging reiterates 2026 full-year revenue guidance of $1.045 bln to $1.097 bln

• Company narrows 2026 Adjusted EBITDA guidance to $236 mln-$240 mln, midpoint unchanged

• Lumexa Imaging raises 2026 Adjusted EPS guidance to $0.86-$0.90 from $0.71-$0.77

Result Drivers

• ADVANCED MODALITIES - Co said advanced modalities reached a record high as a percent of volumes in Q3

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy"

• Wall Street's median 12-month price target for Lumexa Imaging Holdings, Inc. is $17.50, about 25.3% above its November 9 closing price of $13.97

Reuters Recommended Reads

• Nov 8 - RadNet beats Q3 adjusted EPS estimates, lifts 2026 outlook

• Nov 9 - Surgery Partners Inc Q3 revenue misses estimates

• Nov 9 - Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)